DexCom reports Q1 adjusted EPS 32c, consensus 33c

Reports Q1 revenue $1.036B, consensus $1.02B. “To start the year, Dexcom (DXCM) delivered a quarter of strong revenue results and unlocked significant new type 2 coverage,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “As we progress through 2025, we will advance our product portfolio with the launch of our Dexcom G7 15 Day system and continue to advocate for expanded global access to our glucose biosensors.”